EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

Submitted by admin on October 5, 2018 - 9:50am
Source: 
CP Wire
News Tags: 
Bluebird Bio
transfusion-dependent anemia
LentiGlobin
EMA
Europe
Headline: 
EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder
snippet: 
  • LentiGlobin has Orphan Drug status in Europe and the US
  • It has also been granted an accelerated assessment in Europe and Breakthrough Therapy designation in the US
  • LentiGlobin is a one-time gene therapy and is also being studied in sickle cell disease

Do Not Allow Advertisers to Use My Personal information